Gritstone Oncology, Inc. (GRTS): Price and Financial Metrics

Gritstone Oncology, Inc. (GRTS): $11.50

-2.04 (-15.07%)

POWR Rating

Component Grades













Add GRTS to Watchlist
Sign Up

Industry: Biotech


of 506

in industry


  • GRTS scores best on the Growth dimension, with a Growth rank ahead of 61.67% of US stocks.
  • The strongest trend for GRTS is in Stability, which has been heading down over the past 47 weeks.
  • GRTS's current lowest rank is in the Stability metric (where it is better than 5% of US stocks).

GRTS Stock Summary

  • GRTS's went public 2.97 years ago, making it older than just 7.93% of listed US stocks we're tracking.
  • As for revenue growth, note that GRTS's revenue has grown 1,138.92% over the past 12 months; that beats the revenue growth of 98.99% of US companies in our set.
  • In terms of volatility of its share price, GRTS is more volatile than 96.27% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Gritstone bio Inc, a group of peers worth examining would be FIXX, ALPN, SELB, DCPH, and FULC.
  • Visit GRTS's SEC page to see the company's official filings. To visit the company's web site, go to

GRTS Valuation Summary

  • In comparison to the median Healthcare stock, GRTS's price/sales ratio is 165.79% higher, now standing at 10.1.
  • Over the past 36 months, GRTS's price/sales ratio has gone NA NA.
  • Over the past 36 months, GRTS's price/earnings ratio has gone up 3.2.

Below are key valuation metrics over time for GRTS.

Stock Date P/S P/B P/E EV/EBIT
GRTS 2021-08-31 10.1 2.5 -6.5 -5.9
GRTS 2021-08-30 9.8 2.4 -6.2 -5.6
GRTS 2021-08-27 9.9 2.5 -6.3 -5.7
GRTS 2021-08-26 9.8 2.5 -6.2 -5.6
GRTS 2021-08-25 10.0 2.5 -6.4 -5.8
GRTS 2021-08-24 9.4 2.4 -6.0 -5.4

GRTS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GRTS has a Quality Grade of D, ranking ahead of 23.92% of graded US stocks.
  • GRTS's asset turnover comes in at 0.22 -- ranking 190th of 677 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows GRTS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.220 1 -0.671
2021-03-31 0.231 1 -0.816
2020-12-31 0.025 1 -1.309
2020-09-30 0.023 1 -1.050
2020-06-30 0.021 1 -1.011
2020-03-31 0.022 1 -0.900

GRTS Price Target

For more insight on analysts targets of GRTS, see our GRTS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.33 Average Broker Recommendation 1.5 (Moderate Buy)

GRTS Stock Price Chart Interactive Chart >

Price chart for GRTS

GRTS Price/Volume Stats

Current price $11.50 52-week high $35.20
Prev. close $13.54 52-week low $2.54
Day low $11.41 Volume 5,574,200
Day high $14.36 Avg. volume 1,635,938
50-day MA $8.75 Dividend yield N/A
200-day MA $9.87 Market Cap 568.65M

Gritstone Oncology, Inc. (GRTS) Company Bio

Gritstone Oncology, Inc., an immuno-oncology company, engages in developing personalized cancer immunotherapies for various cancer types in the United States. It is developing GRANITE-001, a personalized immunotherapy product for cancer patients; and SLATE-001 for patients with common tumor neoantigens. The company was founded in 2015 and is based in Emeryville, California.

GRTS Latest News Stream

Event/Time News Detail
Loading, please wait...

GRTS Latest Social Stream

Loading social stream, please wait...

View Full GRTS Social Stream

Latest GRTS News From Around the Web

Below are the latest news stories about Gritstone bio Inc that investors may wish to consider to help them evaluate GRTS as an investment opportunity.

Gritstone Announces Private Placement Financing of $55.0 Million

EMERYVILLE, Calif., Sept. 16, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies and vaccines, today announced a $55.0 million private investment in public equity (PIPE) financing from the sale of 5,000,000 shares of its common stock at a price per share of $11.00. Gross proceeds from the PIPE financings total $55.0 million, before deducting placement agent fees and offering

Yahoo | September 16, 2021

3 Explosive Biotech Stocks That Could 10X in 10 Years

A key reason why many people invest in biotech companies is that they expect them to grow much larger. Here's why they chose BioNTech (NASDAQ: BNTX), CRISPR Therapeutics (NASDAQ: CRSP), and Gritstone Bio (NASDAQ: GRTS). Zhiyuan Sun (BioNTech): In the past year, BioNTech shares have more than quintupled on investor enthusiasm surrounding its coronavirus vaccine, Comirnaty, developed jointly with Pfizer (NYSE: PFE).

Yahoo | September 16, 2021

Gritstone to Host Data Update on Neoantigen Oncology Programs for the Treatment of Solid Tumors During ESMO 2021

EMERYVILLE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that it will host a data update webcast for investors and analysts during the European Society of Medical Oncology (ESMO) Annual Meeting 2021, September 17, 2021 at 1:30 p.m. ET. The event will highlight the GRANITE (individualized neoantigen immunotherapy) Phase 1/2 data

Yahoo | September 9, 2021

Gritstone Announces Presentations at Two Investor Conferences in September

EMERYVILLE, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced that Gritstone management will present webcasted company overviews at two upcoming investor conferences in September. Conference: H.C. Wainwright 23rd Annual Global Investment Conference Date and Time: Monday, September 13, 2021 at 7:00 a.m. ETPresenter: Andrew Allen, M.D.

Yahoo | September 7, 2021

Gritstone and CEPI Announce Agreement to Advance Second-Generation COVID-19 Vaccine Program (CORAL) Against SARS-CoV-2 Variants of Concern

CEPI to fund Gritstone’s work on second-generation vaccines against SARS-CoV-2, the virus causing COVID-19, including a clinical trial in South Africa and manufacturing optimizationGritstone’s second-generation vaccines include self-amplifying mRNA (SAM) to deliver multiple antigens (spike protein plus additional sequence from non-spike genes) providing the potential for deep, broad, and durable immunity against SARS-CoV-2 variantsGritstone’s CORAL Phase 1 program – which includes the CEPI-funde

Yahoo | August 17, 2021

Read More 'GRTS' Stories Here

GRTS Price Returns

1-mo 52.72%
3-mo 20.42%
6-mo -11.27%
1-year 248.48%
3-year N/A
5-year N/A
YTD 191.88%
2020 -56.08%
2019 -41.94%
2018 N/A
2017 N/A
2016 N/A

Continue Researching GRTS

Here are a few links from around the web to help you further your research on Gritstone Oncology Inc's stock as an investment opportunity:

Gritstone Oncology Inc (GRTS) Stock Price | Nasdaq
Gritstone Oncology Inc (GRTS) Stock Quote, History and News - Yahoo Finance
Gritstone Oncology Inc (GRTS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8817 seconds.